Biodexa Pharmaceuticals Plc (BDRX) Form 6-K — Jul 29, 2026
Biodexa Pharmaceuticals shareholders approved a massive one-for-10,000 reverse stock split of ordinary shares, effective July 30, 2026, alongside authorizing the allotment of up to £25 million for future share issuances. The reverse split reduces the number of outstanding ordinary shares to approximately 51.45 million while maintaining the nominal value of £0.000001 per share. Concurrent with the split, the ratio of ordinary shares per American Depositary Share (ADS) changed by a factor of 10,000, moving from 500,000:1 to 50:1.
Key figures
- New ads ratio
- 50:1
- Old ads ratio
- 500,000:1
- Reverse split ratio
- 1:10,000
- Post split ads outstanding
- 1,029,063
- Allotment authorization gbp
- 25000000
- Post split shares outstanding
- 51,453,281
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.